The primary takeaways from this study’s findings were that the expression of exosomal miR-16-5p and tissular PD-L1 was related to both T-stage (tumor size stage) and the therapeutic benefit of PD-L1 inhibitors in PD-L1-positive LUAD patients. This evidence concerns the gene CD274 and neoplasm.